{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:44:35Z","timestamp":1770471875763,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.1016\/s0952-7915(99)00012-6","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T17:27:54Z","timestamp":1027618074000},"page":"584-588","source":"Crossref","is-referenced-by-count":62,"title":["Monoclonal antibody drug conjugates in the treatment of cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Pamela A","family":"Trail","sequence":"first","affiliation":[]},{"given":"Albert B","family":"Bianchi","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0952-7915(99)00012-6_BIB1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.8327892","article-title":"Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates","volume":"261","author":"Trail","year":"1993","journal-title":"Science"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB2","first-page":"4530","article-title":"Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats","volume":"57","author":"Sj\u00f6gren","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB3","first-page":"2925","article-title":"Targeted therapy with a novel enediyene antibiotic calicheamicin \u03b8I1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma","volume":"58","author":"Lode","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB4","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB5","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB6","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.1998.16.5.1788","article-title":"Monoclonal antibody therapy for resected Dukes\u2019 C colorectal cancer: seven-year outcome of a multicenter randomized trial","volume":"16","author":"Riethmuller","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB7","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-3659(97)00237-X","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"53","author":"Jain","year":"1998","journal-title":"J Control Release"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB9","series-title":"Monoclonal Antibody-Based Therapy of Cancer","first-page":"397","article-title":"Immunoconjugate therapy of solid tumors: studies with BR96-doxorubicin","author":"Saleh","year":"1998"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB10","first-page":"3336","article-title":"Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics","volume":"53","author":"Hinman","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/bc980100i","article-title":"Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates","volume":"10","author":"King","year":"1999","journal-title":"Bioconjug Chem"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0304-3835(97)00326-1","article-title":"Anti-HER2 immunoliposomes for targeted therapy of human tumors","volume":"118","author":"Park","year":"1997","journal-title":"Cancer Lett"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB13","first-page":"3320","article-title":"In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma","volume":"58","author":"Lopes de Menezes","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<723::AID-IJC16>3.0.CO;2-L","article-title":"Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model","volume":"80","author":"Tseng","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB15","first-page":"51","article-title":"Pretreatment with a monoclonal antibody\/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors","volume":"5","author":"Hornick","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.275.5299.547","article-title":"Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature","volume":"275","author":"Huang","year":"1997","journal-title":"Science"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB17","first-page":"4646","article-title":"Infarction of solid Hodgkin\u2019s tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature","volume":"58","author":"Ran","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/00001622-199811000-00014","article-title":"Chemotherapy targeted to tumor vasculature","volume":"10","author":"Arap","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB20","first-page":"371","article-title":"Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies","volume":"5","author":"Matsuno","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB21","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/jm9600398","article-title":"The enediyne antibiotics","volume":"39","author":"Smith","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/0959-8049(93)90399-Z","article-title":"Antitumour activity of an immunoconjugate composed of anti-human astrocytoma monoclonal antibody and neocarzinostatin","volume":"3","author":"Kondo","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0304-3835(97)00401-1","article-title":"Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using monoclonal antibody-drug conjugate","volume":"122","author":"Okamoto","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0748-7983(05)80070-8","article-title":"The effect of intravenous and intra-tumoural chemotherapy using a monoclonal antibody-drug conjugate in a xenograft model of pancreatic cancer","volume":"21","author":"Otsuji","year":"1995","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/978-1-4615-5357-1_66","article-title":"Monoclonal antibody 138H11 against gamma-glutamyltransferase provides a possible tool for targeting calicheamicin theta to renal cell carcinomas","volume":"451","author":"Schmidt","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB26","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/ac970035q","article-title":"Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption\/ionization mass spectrometry and electrospray ionization mass spectrometry","volume":"69","author":"Siegel","year":"1997","journal-title":"Anal Chem"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ddr.430340209","article-title":"Site-directed delivery of anthracyclines for cancer therapy","volume":"34","author":"Trail","year":"1995","journal-title":"Drug Dev Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/bc00024a015","article-title":"(6-maleimidocaproyl)- hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin","volume":"4","author":"Willner","year":"1993","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.1999.17.2.478","article-title":"Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer","volume":"17","author":"Tolcher","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB30","first-page":"2183","article-title":"Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Ley- related cell surface antigen","volume":"50","author":"Hellstr\u00f6m","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB31","doi-asserted-by":"crossref","unstructured":"Hellstr\u00f6m I, Hellstr\u00f6m KE, Siegall CB, Trail PA: Immunoconjugates and immunotoxins for therapy of carcinomas. In Advances in Pharmacology, vol 33, edn 1. Edited by August JT, Anders MW, Murad F, Coyle JT. San Diego: Academic Press; 1995:349\u2013388.","DOI":"10.1016\/S1054-3589(08)60674-2"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB32","first-page":"115","article-title":"Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen","volume":"59","author":"Stan","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB33","first-page":"4192","article-title":"Anthracycline immunoconjugates prepared by a site specific linkage via an amino-dextran intermediate carrier","volume":"51","author":"Shih","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB34","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C","article-title":"HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro","volume":"75","author":"Omelyanenko","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/js9604467","article-title":"Antitumoral activity of liposomes and immunoliposomes containing 5- fluorouridine prodrugs","volume":"86","author":"Crosasso","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0005-2736(91)90201-I","article-title":"Pharmacokinetics of stealth versus conventional liposomes: effect of dose","volume":"1068","author":"Allen","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB37","first-page":"1541","article-title":"Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat","volume":"282","author":"Huwyler","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0005-2736(95)00138-S","article-title":"Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures","volume":"1239","author":"Hansen","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/bi962148u","article-title":"Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro","volume":"36","author":"Kirpotin","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB40","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0959-8049(96)00423-6","article-title":"New perspectives in clinical oncology from angiogenesis research","volume":"14","author":"Folkman","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/(SICI)1097-0215(19971210)73:6<865::AID-IJC17>3.0.CO;2-3","article-title":"Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate","volume":"73","author":"Olson","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB42","first-page":"183","article-title":"Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells","volume":"59","author":"Arora","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/S0952-7915(99)00012-6_BIB43","first-page":"1952","article-title":"Vascular endothelial growth factor as a marker of tumor endothelium","volume":"58","author":"Brekken","year":"1998","journal-title":"Cancer Res"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791599000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791599000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T14:56:23Z","timestamp":1578927383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791599000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["S0952791599000126"],"URL":"https:\/\/doi.org\/10.1016\/s0952-7915(99)00012-6","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}